Par Alleges 'Shocking' Trade Secret Theft By QuVa Pharma
Executive Summary
Par says former employees who founded QuVa used Par's trade secrets to develop a vasopressin product, which FDA has added to its list of ingredients for drug compounding.
You may also be interested in...
Compounding Draft Guidance May End Par's Suit Against US FDA
Par says FDA shouldn't have authorized a compounded version of Vasostrict, but parties have asked court to wait until March, when a guidance is expected that may resolve the company's concerns.
Pfizer Ex-Marketing Director Agrees To Injunction, Ending Trade Secret Suit
Former Pfizer employee has joined Sun Pharma as it launches ophthalmic drug and expands its specialty portfolio, which includes Phase III monoclonal antibody for treatment of psoriasis.
Amgen Alleges 'Massive Conspiracy' By Employees Who Joined Coherus And KBI
Details emerge on the breadth of Amgen's complaint against Coherus and former Amgen employees; trade secrets on Neulasta pricing and contract strategies allegedly stolen via USB drives.